Inflammatory Bowel Disease Outcomes in Northern Iran: A Retrospective Cohort Study of Remission, Complications, and Treatment Strategies.

Background: Inflammatory bowel disease (IBD), encompassing Crohn′s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory condition affecting the gastrointestinal tract. While significant progress has been made in managing IBD, the long‐term outcomes remain heterogeneous, prompting this...

Descripción completa

Detalles Bibliográficos
Publicado en:BioMed Research International Vol. 2026; pp. 1 - 12
Autores principales: Hoseinialiabadi, Poria, Maleki, Iradj, Fakheri, Hafez, Ebrahimi, Mahboobe, Yousefi Abdolmaleki, Elham, Taghvaei, Tarang, Shokri-Afra, Hajar, Banerjee, Baisakhi
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell 1/8/2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=190770289&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 190770289
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        23146133
        FT2T
      jtl: BioMed Research International
      issn: 23146133
      maglogo: N
    pubinfo:
      dt: 1/8/2026
      vid: 2026
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        190770289
        190770289
        190770289
        10.1155/bmri/5363565
        190770289
      ppf: 1
      ppct: 11
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Inflammatory Bowel Disease Outcomes in Northern Iran: A Retrospective Cohort Study of Remission, Complications, and Treatment Strategies.
      aug:
        au:
          Hoseinialiabadi, Poria
          Maleki, Iradj
          Fakheri, Hafez
          Ebrahimi, Mahboobe
          Yousefi Abdolmaleki, Elham
          Taghvaei, Tarang
          Shokri-Afra, Hajar
          Banerjee, Baisakhi
        affil: Gut and Liver Research Center, , Non-Communicable Disease Research Institute, , Mazandaran University of Medical Sciences, , Sari, Iran, mazums.ac.ir
      sug:
        subj:
          Inflammatory Bowel Diseases Therapy
          Treatment Outcomes
          Disease Remission
          Inflammatory Bowel Diseases Complications
          Health Care Delivery
          Disease Management
          Human
          Retrospective Design
          Prospective Studies
          Descriptive Statistics
          Data Analysis Software
          Quantitative Studies
          Analysis of Variance
          Chi Square Test
          Wilcoxon Signed Rank Test
          T-Tests
          Male
          Female
          Adult
          Middle Age
          Iran
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Male
          Female
      ab: Background: Inflammatory bowel disease (IBD), encompassing Crohn′s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory condition affecting the gastrointestinal tract. While significant progress has been made in managing IBD, the long‐term outcomes remain heterogeneous, prompting this cohort study. Methods: A retrospective analysis was performed on patients with IBD registered between 2000 and 2023. Clinical data, including demographics, disease activity, remission rates, therapeutic approaches, and complications, were collected. Results: Among 600 enrolled patients, 72.8% were diagnosed with UC. Both patients with UC and those with CD showed improvements in endoscopic severity by the end of follow‐up (p < 0.001). Clinical remission was achieved by 96.3% of patients with UC and 91.2% of those with CD during the last 6 months of follow‐up (p = 0.046). Disease progression occurred in 22.1% of patients with CD and 18% of those with UC (p = 0.100). Gastrointestinal complications were more prevalent in patients with CD (25.6% vs. 1.6%, p < 0.001). Relapse remained high, with 86.7% of patients with UC and 92.6% of those with CD experiencing relapses at least once during follow‐up, particularly those with severe baseline disease (p < 0.01). Biologic therapies were used more frequently (p < 0.01) and initiated earlier in patients with CD (p = 0.031). Conclusion: The study showed significant clinical improvement, yet many patients, particularly those with severe initial disease, had incomplete remission and frequent relapses, necessitating more effective long‐term management strategies. The distinction between CD and UC highlights the need for specialized treatments.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N